It provides for up to$ 2.4 billion in milestone payments, in addition to$ 200 million upfront as well as royalties if approved.It is also at least the fifth out-licensing deal potentially worth more than$ 1 billion clinched by a Chinese biotech.... The antibody also shows promise in tackling bladder and stomach tumours. Other notable deals include a Novartis AG agreement worth up to$ 2.2 billion for a BeiGene Ltd drug.... Junshi and Innovent did not respond to requests for comment. Legend was